These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 24295975)
1. Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II. Xu B; Wang L; González-Molleda L; Wang Y; Xu J; Yuan Y Antimicrob Agents Chemother; 2014; 58(1):563-73. PubMed ID: 24295975 [TBL] [Abstract][Full Text] [Related]
2. Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus. González-Molleda L; Wang Y; Yuan Y Antimicrob Agents Chemother; 2012 Feb; 56(2):893-902. PubMed ID: 22106228 [TBL] [Abstract][Full Text] [Related]
3. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ mBio; 2018 May; 9(3):. PubMed ID: 29739902 [TBL] [Abstract][Full Text] [Related]
4. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication. Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M J Virol; 2017 May; 91(10):. PubMed ID: 28275189 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a small-molecule inhibitor of KSHV lytic replication from the MMV pandemic response box. Okpara MO; Weaver F; Whitehouse A; Veale CGL; Edkins AL Antiviral Res; 2024 Oct; 230():105990. PubMed ID: 39154751 [TBL] [Abstract][Full Text] [Related]
6. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation. Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497 [TBL] [Abstract][Full Text] [Related]
7. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research]. Watanabe T; Fujimuro M Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932 [TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy. Andrei G; Snoeck R Curr Opin Infect Dis; 2015 Dec; 28(6):611-24. PubMed ID: 26524334 [TBL] [Abstract][Full Text] [Related]
15. Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Zhu W; Burnette A; Dorjsuren D; Roberts PE; Huleihel M; Shoemaker RH; Marquez VE; Agbaria R; Sei S Antimicrob Agents Chemother; 2005 Dec; 49(12):4965-73. PubMed ID: 16304159 [TBL] [Abstract][Full Text] [Related]
16. The DNase Activity of Kaposi's Sarcoma-Associated Herpesvirus SOX Protein Serves an Important Role in Viral Genome Processing during Lytic Replication. Uppal T; Meyer D; Agarwal A; Verma SC J Virol; 2019 Apr; 93(8):. PubMed ID: 30728255 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling. Yan Q; Shen C; Qin J; Li W; Hu M; Lu H; Qin D; Zhu J; Gao SJ; Lu C J Virol; 2016 Oct; 90(19):8739-53. PubMed ID: 27440900 [TBL] [Abstract][Full Text] [Related]
19. Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase. Cheng F; He M; Jung JU; Lu C; Gao SJ J Virol; 2016 Jul; 90(14):6515-6525. PubMed ID: 27147746 [TBL] [Abstract][Full Text] [Related]
20. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection. Katano H Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]